Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty

Sarepta Therapeutics Inc. (SRPT) has disclosed a new risk, in the Corporate Activity and Growth category.

Claim 30% Off TipRanks

Sarepta Therapeutics Inc. faces execution risk around its July 2025 strategic restructuring, as the 36% workforce reduction and revised cost structure may not yield the anticipated R&D and SG&A savings. Failure to capture these efficiencies, coupled with potential operational disruption, higher employee turnover and weakened talent attraction, could pressure its business strategy, operating results and overall financial condition.

The average SRPT stock price target is $21.06, implying 29.04% upside potential.

To learn more about Sarepta Therapeutics Inc.’s risk factors, click here.